

FEDERAL DEPOSIT INSURANCE CORPORATION

Sunshine Act Meeting; Notice of a Matter To Be Withdrawn From Consideration at an Agency Meeting

Pursuant to the provisions of the "Government in the Sunshine Act" (5 U.S.C. 552b), notice is hereby given that the following matter will be withdrawn from the "Discussion Agenda" at the Federal Deposit Insurance Corporation's Board of Directors open meeting scheduled to be held at 10:00 a.m. on Tuesday, April 28, 1998:

Memorandum re: General Counsel Opinion Regarding Interest Charges by Interstate State Banks.

Dated: April 22, 1998.
Federal Deposit Insurance Corporation.

Robert E. Feldman,

Executive Secretary.

[FR Doc. 98-11196 Filed 4-23-98; 8:45 am]

BILLING CODE 6714-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Early Hearing Detection and Intervention Teleconference meetings

The National Center for Environmental Health (NCEH) of the Centers for Disease Control and Prevention (CDC) announces the following bi-monthly meetings.

Name: Teleconference meetings of the Ad Hoc Group for Early Hearing Detection and Intervention (EHDI).

Times and Dates: 2 p.m.-3 p.m., May 5, 1998; 2 p.m.-3 p.m., July 7, 1998; 2 p.m.-3 p.m., September 1, 1998; 2 p.m.-3 p.m., November 3, 1998; 2 p.m.-3 p.m., January 5, 1999; 2 p.m.-3 p.m., March 2, 1999.

Place: National Center for Environmental Health, Division of Birth Defects and Developmental Disabilities, Room 2103A, Building 101, 4770 Buford Highway, NE, Atlanta, Georgia 30341, telephone 770/488-7400.

Status: Open for participation by anyone with an interest in EHDI. All participants in the bi-monthly conference calls are, by definition, members of the Ad Hoc Group for Early Hearing Detection and Intervention. Persons wishing to participate must e-mail (ehdi@cdc.gov) or fax (770/488-7361) their request. Within one week of each teleconference, participants will be notified of the toll-free teleconference phone number, a caller code and the agenda. Each participant will have the responsibility to call in to connect to the conference call.

Purpose: This meeting will provide a forum for persons associated with EHDI programs to report and review relevant activities. Each conference call will be

comprised of a series of scheduled presentations. Each presentation will be followed by a brief question and answer period. The agenda for the conference call will be determined by the Division of Birth Defects and Developmental Disabilities in collaboration with the Office on Disability and Health, NCEH; the National Institute on Deafness and Communicative Disorders, National Institutes of Health; the Bureau of Maternal and Child Health, Health Resources and Services Administration; Office of Special Education and Rehabilitative Services, Department of Education; and others interested in early hearing detection programs. Suggestions and feedback are invited by the conference call planners. Participants requesting to be on the agenda or to make written comments can send their requests or comments to the e-mail address or fax numbers noted above.

Matters to be Discussed: Topics to be discussed during the meetings include progress on State and National activities to implement EHDI programs; progress on establishing State and National data systems on EHDI; and guidelines for establishing screening, diagnosis, and intervention protocols.

Contact Person for More Information: June Holstrum, Ph.D., Division of Birth Defects and Developmental Disabilities, NCEH, CDC, 4770 Buford Highway, NE, M/S F-15, Atlanta, Georgia 30341, telephone 770/488-7401, e-mail ehdi@cdc.gov, fax 770/488-7361.

Dated: April 21, 1998.

John C. Burckhardt,

Acting Director, Management Analysis and Services Office Centers for Disease Control and Prevention (CDC).

[FR Doc. 98-11065 Filed 4-24-98; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Gastrointestinal Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Gastrointestinal Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on May 28 and 29, 1998, 9 a.m. to 5 p.m.

Location: Holiday Inn, Versailles Ballrooms I and II, 8120 Wisconsin Ave., Bethesda, MD.

Contact Person: Joan C. Standaert, Center for Drug Evaluation and Research (HFD-110), Food and Drug Administration, 5600 Fishers Lane, Rockville MD 20857, 419-259-6211, or John B. Schupp (HFD-21), 301-443-5455, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12538. Please call the Information Line for up-to-date information on this meeting.

Agenda: On May 28, 1998, the committee will discuss biologics license application, 98-0012, Centocor, Inc.'s, *Avakine*TM (Infliximab), for treatment of patients with Crohn's disease. An indication is sought to: (1) Reduce signs and symptoms in patients with moderate to severe disease activity in whom conventional therapies are inadequate, and (2) close enterocutaneous fistulas. On May 29, 1998, the committee will hold a general discussion on guidance for the study of drugs to treat Crohn's disease.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by May 21, 1998. Oral presentations from the public will be scheduled between approximately 9 a.m. and 10 a.m., on May 28, 1998. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before May 21, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: April 17, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98-11087 Filed 4-24-98; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 042098F]

Endangered Species; Permits

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.